Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Wave Of Clinical Trials May Throw Indian Regulators Off Balance - DIA Conference

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - India's ability to handle a growing number of clinical trial applications has reached a tipping point as ethics committees, regulators and other stakeholders struggle to meet demand which is expected to double in 2008, industry officials said

You may also be interested in...



PharmAsia News Notable Notes: Kotak Initiates Coverage Of Five Indian CMO, CRO Firms

NEW DELHI - Efforts by five smaller Indian drug companies to attract contract research and manufacturing stand to benefit from multinational firms cost-cutting efforts in sourcing active pharmaceutical ingredients and increased clinical trials in the country

PharmAsia News Notable Notes: Kotak Initiates Coverage Of Five Indian CMO, CRO Firms

NEW DELHI - Efforts by five smaller Indian drug companies to attract contract research and manufacturing stand to benefit from multinational firms cost-cutting efforts in sourcing active pharmaceutical ingredients and increased clinical trials in the country

Negative Perceptions of Clinical Trials In India Persist – Clinical Trials Panel

SAN FRANCISCO - Companies looking to initiate clinical trials in India must tread lightly when navigating ethics committees, according to panelists at a recent conference on various aspects of entering clinical trials in Asia

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel